Question-and-Answer Session
Operator
(Operator instructions) The first question is from May-Kin Ho from Goldman Sachs. Please proceed with your question. May-Kin Ho?
Our next question is from Joel Sendek from Lazard Capital. Please proceed with your question.
Joel Sendek – Lazard Capital Markets
Thanks. A couple of questions. First, I just want to make sure I had the number right with regard to the cash for the Lev acquisition because I didn’t see it in the press release. You said $385 million?
Vincent Milano
Correct.
Joel Sendek – Lazard Capital Markets
Okay. Thanks for that. And then, I know you are going to do the call next week but can you just tell us – do you think the launch will occur next year? I know you are may be doing your guidance conservatively. Is it possible that the launch could occur this year?
Vincent Milano
Dan, would you like to answer that question?
Dan Soland
Sure. We’ll have a chance to talk a lot more about this next week as we are very busy tying up a few loose ends. And the plan is to launch in 2008.
Joel Sendek – Lazard Capital Markets
Okay great, thanks. And then just quickly on maribavir, the – for the solid organ transplant, is it possible that enrollment will complete this year?
Vincent Milano
Tom?
Tom Doyle
Good morning, Joel. The enrollment in the solid organ study is going well. And the next you’ll hear from us will be when we complete enrollment, but I am not going to put a date on that today.
Joel Sendek – Lazard Capital Markets
Okay. Thank you.
Vincent Milano
Thanks, Joel.
Operator
Our next question is from Rachel McMinn from Cowen and Company. Please proceed with your question.
Rachel McMinn – Cowen and Company
Yes, thanks very much and I, again, I have a Cinryze question without trying to get into too many specifics but can you talk about how many patients you have identified to you right now? You have talked about I think a little over 100 patients, somewhere around 115 patients in the clinical trial. So, I guess how many outside of clinical trials have been identified to you?
Vincent Milano
So, Rachel, I’ll let Dan provide some color. We are not going to be in a position today to roll out the number of patients that we’ve identified. We’ll talk about the number of patients that are in the study to give you some specifics on that. I think it’s safe to say and important to note that since the product was approved on October 10th and since we closed the acquisition, we’ve had a tremendous amount of interest from patients who have this debilitating and life-threatening disease. And so we are actively receiving those calls into our Cinryze Solutions. And I am going to put a plug in here for Cinryze Solutions – any HAE patient who is listening, please go to cinryze.com or dial 1-877-945-1000 and we’ll be very interested to begin working with you to get you Cinryze.
- To read the full transcript on Seeking Alpha, click here »
